An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
Clinical trial NCT07233213 · RECRUITING
Trial details
- NCT number
- NCT07233213
- Sponsor
- Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-24
- Primary completion
- 2026-12-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.